In line with this finding, one study has reported that an increase in IL-17A can promote lung cancer growth by promoting inflammation, which results in resistance to anti-PD1 therapy and sensitizes tumors to cytokine and neutrophil depletion [39]. This evidence concerns the gene IL17A and lung cancer.